AI Article Synopsis
- The study aimed to assess how the maximum standardized uptake value (SUVmax) from 18F-FDG PET/CT scans could predict disease progression in patients with metastatic colorectal cancer, compared to traditional markers like CEA and CA 19-9.
- Involving 70 untreated patients, the research found that both SUVmax and CA 19-9 were independently significant in forecasting disease progression within a year, with a specific cut-off point of SUVmax at 4.1 distinguishing between patients with better or worse outcomes.
- The results suggest using SUVmax as a new prognostic tool to identify patients at higher risk for rapid disease advancement, allowing for more personalized treatment strategies in metastatic
Article Abstract
Objective: The aim of the study was to evaluate the prognostic value of the maximum standardized uptake value (SUVmax) of 18F-Fluorodeoxyglucose (18F-FDG) PET/CT in patients with metastatic colorectal cancer, and to compare it with classical prognostic markers.
Materials And Methods: The study included 70 patients with metastatic colorectal cancer who had not been treated for the metastatic disease. The patients underwent 18F-FDG PET/CT as part of their routine diagnostic reevaluation. During the analysis, the value of the largest tumor diameter and SUVmax was determined for the lesion with the highest SUVmax observed. The values of CEA and CA 19-9 were recorded 7 days before the PET/CT analysis.
Results: SUVmax and Carbohydrate antigen (CA)19-9 were found to be independent prognostic markers of disease progression within 12 months. Based on the Receiver Operating Characteristics (ROC) curve analysis, the patients could be divided into two groups: SUVmax≤4.1 vs. SUVmax>4.1. Patients with SUVmax values of 4.1 or less had significantly better progression-free survival within 12 months with an HR (95% CI) of 2.97 (1.4-6.3), relative to patients with SUVmax values above 4.1.
Conclusion: SUVmax may be used as a novel prognostic marker of disease progression among patients with metastatic colorectal cancer. Values of SUVmax can be used to select patients with a more aggressive type of disease and higher risk for progression within 12 months of PET/CT analysis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5644/ama2006-124.278 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!